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around operationalizing compliance/adherence and persistence
deﬁnitions. Comments were incorporated and the ﬁnal opera-
tional deﬁnitions posted for consensus on the website. RESULTS:
Medication Compliance (Synonym: Adherence) is the extent to
which a patient acts in accordance with the prescribed interval
and dose as well as dosing regimen. The unit of measure for com-
pliance is administered doses per deﬁned period of time, reported
as a proportion (%) of prescribed doses (D) taken at the pre-
scribed time interval (T) as measured by the period of time, i.e.,
% of TD, measured by percentage. CONCLUSION: Medication
Persistence is the duration of time patient remains on treatment
i.e. accumulation of time from initiation to discontinuation of
therapy, where patient is deﬁned as a discontinuer if medications
were not taken within a predeﬁned permissible time gap.
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OBJECTIVES: The objective of this study was to evaluate the
relationship between pharmaceutical product price and its ability
to improve patient health related quality of life (HRQoL).
METHODS: Comprehensive review of the literature was con-
ducted to identify all HRQoL studies of pharmaceutical prod-
ucts that utilized a test-retest experimental approach. Effect sizes
were calculated from data available for 31 products, represent-
ing a brand range of therapeutic areas. Wholesale acquisition
cost (WAC), number of months on market, and number of prod-
ucts in therapeutic class was collected for each product. Cost per
day of therapy was calculated using recommended starting dose
in the labeling. Multivariate linear regression models were con-
structed where either WAC or cost per day of therapy at rec-
ommended starting dose was the dependent variable and effect
size, number of months on market, and number of products in
therapeutic class were independent variables. Diagnostics were
performed to verify model assumptions. RESULTS: Using mul-
tivariate linear regression, average effect size, number of prod-
ucts in therapeutic class, and number of months on market were
signiﬁcant predictors of WAC [b (average effect size) = 167.13,
p < 0.0001; b (number in class) = 14.85, p < 0.0001; b (number
of months on market) = -0.47, p = 0.0001; R-square = 0.65].
Diagnostics revealed no violations of model assumptions. CON-
CLUSIONS: There is sufﬁcient evidence to suggest that there is
a direct relationship between a pharmaceutical product’s ability
to cause improvement in HRQoL and the price of the product,
measured using average effect size and WAC, respectively. In
addition, the number of products within a therapeutic class and
their length of time on the market were inﬂuential of drug price.
Further research should be conducted to evaluate the impact of
prescription medications on HRQoL, and, to identify and char-
acterize the effects of drug and marketplace variables on drug
prices.
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OBJECTIVE: To investigate the quantity and quality of Patient
Reported Outcome (PRO) claims in pharmaceutical advertise-
ments in 2 Thai medical journals. METHOD: A retrospective
review of all pharmaceutical advertisements in the 2004 issues
of 2 Thai medical journals (Clinic and Pharmatime) was per-
formed by 3 trained pharmacists. Two reviewers independently
reviewed the advertisements. If the reviewers disagreed the ﬁnal
decision was made by the third reviewer. All distinctive phar-
maceutical advertisements were classiﬁed into claim advertise-
ment or reminder advertisement. PRO claims and economic
claims were also identiﬁed. Then, the advertisements were cate-
gorized according to their reference statuses. Finally, the review-
ers evaluated whether the cited references provided substantial
evidence to support the claims. RESULTS: From 183 advertise-
ments reviewed, there were 48 distinctive advertisements. Forty-
ﬁve (0.94%) and three (0.06%) of the advertisements were
classiﬁed as claim advertisement and reminder advertisement,
respectively. Nineteen (0.42%) of the claim advertisements con-
tained PRO claims while two (0.04%) of the claim advertise-
ments contained economic claims. The result indicated that only
16 (0.36%) of the claim advertisements cited at least one pub-
lished article retrievable from Medline as references, while the
remaining 29 (0.64%) contained no reference or cited package
inserted or non-published data on ﬁle as references. When
looking closely at PRO claims, it was found that 12 (0.63%) of
the PRO claims were misleading because the outcomes stated in
the claims was not supported by the given references. In addi-
tion, there was not sufﬁcient evidence to support all 2 economic
claims. CONCLUSION: More than half of the PRO claims were
misleading. Practitioners should be cautious in assessment of
PRO claim advertisements in medical journal. There is also a
substantial need for more rigorous regulation of PRO claims.
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OBJECTIVE: To determine the cost-effectiveness of escitalopram
in the treatment of Generalized Anxiety Disorder (GAD) in
Canada. GAD places a signiﬁcant burden on primary care
resources, exhibiting an 8% prevalence rate among patients seen
by primary care clinicians. METHODS: A 24-week decision tree
analytic model was constructed using Tree Age Data® Pro Suite.
Patients received treatment for GAD with either escitalopram or
generic paroxetine. Clinical rates were determined from a review
of the literature; expert opinion guided model development in
establishing decision pathways. Tolerance/intolerance to the
initial drug was incorporated into the model, which included
augmenting, titrating or switching comparators. Psychotherapy
was used for patients not responding to either drug, or to the
combination of either drug augmented with a benzodiazepine.
Costs were measured in undiscounted 2005 Canadian dollars
(CAD). Resources were valued using standard Canadian sources.
Effectiveness was measured in Symptom Free Days (SFDs).
Analyses were performed from two perspectives: the Ontario
Ministry of Health and Long Term Care (MoH—included all
direct costs: drugs, physicians visits), and societal (SOC-included
direct plus indirect costs weighted using the average industrial
wage). Extensive sensitivity analyses (1-way and probabilistic)
were conducted. RESULTS: Results shown are preliminary. Base
case analyses (MoH perspective) yielded an incremental cost of
$24 for escitalopram (expected cost = $713 for 85 SFDs) over
